-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Triple-negative breast cancer (TNBC) with negative expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor (HER2 ) accounts for about 15% of all breast cancers, of which metastatic three The survival prognosis of patients with negative breast cancer is poor.
Breast Cancer Immunity Researchers recently launched a phase III clinical study to investigate the therapeutic effect of Sacituzumab govitecan on patients with metastatic TNBC.
In this phase III clinical study, researchers compared Sacituzumab govitecan with first-line single-agent chemotherapy (eribulin, vinorelbine, capecitabine, or gemcitabine) for relapsed or refractory metastatic triple-negative breast cancer The treatment effect of the patient, chemotherapy drugs are selected by the clinician, and the patient has no brain metastasis.
468 patients participated in the study, including 235 patients in the Sacituzumab govitecan group and 233 patients in the first-line chemotherapy group.
The median progression-free survival in the Sacituzumab-govitecan group was 5.
Studies believe that for patients with metastatic triple-negative breast cancer who have previously been treated with paclitaxel, the ADC drug Sacituzumab-govitecan is superior to single-agent chemotherapy in terms of progression-free survival and overall survival, but adverse events of bone marrow suppression and diarrhea are more common.
For patients with metastatic triple-negative breast cancer who have previously been treated with paclitaxel, the ADC drug Sacituzumab-govitecan is superior to single-agent chemotherapy in terms of progression-free survival and overall survival, but adverse events of bone marrow suppression and diarrhea are more common.
Original source:
Aditya Bardia et al.
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancers.
Leave a message here
